Search
Theravance Biopharma Inc
TBPHAdd to Watchlist
16.860USD
+0.010+0.06%
Close 07-31 16:00（ET）Quotes delayed by 15 min
873.82MMarket Cap
7.39P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Theravance Biopharma Inc is 6.80, ranking 125 out of 155 in the Pharmaceuticals industry. The average price target is 27.00, with a high of 42.00 and a low of 13.00.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
17.667
Target Price
+4.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Theravance Biopharma Inc
TBPH
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Theravance Biopharma Inc's expected revenue for the next quarter?
Theravance Biopharma Inc's expected revenue is 21.60M.
What is Theravance Biopharma Inc's price target?
Analysts forecast that Theravance Biopharma Inc's price target is USD 27.00, with the highest forecast at USD 42.00 and the lowest forecast at USD 13.00.
How have Theravance Biopharma IncTBPH's recent earnings per share performed?
The market expectation was USD -0.10, while Theravance Biopharma IncTBPH's earnings per share (EPS) for the previous quarter was USD 1.20. EPS for the next quarter is expected at USD 0.05.
What is the analyst rating for Theravance Biopharma Inc?
Based on the ratings of Theravance Biopharma Inc's stock from 5 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.